APRE
APRE
Last
$0.60
Day
+8.3%
1y
-62.2%
5y
-99.5%
52w
-67.0%
SPY YTD
+13.3%
Sec
—
Earnings
2026-11-1132d
EMA 21
0.70
EMA 50
0.72
EMA 200
0.89
20d high
-33.8%
5y high
-99.5%
5y range
0th
Positions held
Your positionsAPRE isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$0.67
Stop
$0.47
Stop distance
22.2%
Target vs last
+10.8%
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Aprea Therapeutics to Present at October Conferences
2026-09-10 · Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-28 · Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
2026-08-12 · Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patternsAPRE · daily-24.3% over 14 sessions
Close EMA21 EMA50 EMA200